title: [Roles of potassium channel in effects of resveratrol on isolated myocardial contractility and heart rate research in guinea pig].
abstract: OBJECTIVE
  To study the effects of resvaratrol derivatives on spontaneous HR and CF of isolated guinea pig atrium.
  
  
  METHODS
  The dose-effect curve of resvaratrol was observed. The possible mechanism of potassium channels responsible for changes of CF and HR after administering with resvaratrol was measured.
  
  
  RESULTS
  Resvaratrol reduced the spontaneous HR and weakened the CF in a dose-dependent manner ranging from 10(-6) to 3 x 10(-4) mol x L(-1) (P < 0.05). As compared with Res group, the effects were partly blocked by Gli (P < 0.05) and TEA (P < 0.01), but not blocked by 4-AP, BaCl2, Atropine.
  
  
  CONCLUSIONS
  Resvaratrol can induce negative chronotropic action and negative (inotropic action. The mechanism(s) may relate to the opening of K(ATP) and Kc(Ca).
authors: Department of Physiology, Basic Medical College, Hebei Medical University, Shijiazhuang 050091, China. ccwgy@163.com
authors: Gui-ying
authors: GY
authors: Wang
authors: Cui-miao
authors: CM
authors: Song
authors: Li-nan
authors: LN
authors: Zhang
authors: Qian
authors: Q
authors: Li
authors: Hua
authors: H
authors: Yue
authors: Jing-kun
authors: JK
authors: Feng
authors: Na
authors: N
authors: Wang
mesh_terms: D000818:Animals; D017609:Barium Compounds / Q000494:pharmacology; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D002712:Chlorides / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005905:Glyburide / Q000494:pharmacology; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects*; D066298:In Vitro Techniques; D054086:KATP Channels / Q000037:antagonists & inhibitors; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D010946:Plants, Medicinal / Q000737:chemistry; D026902:Potassium Channel Blockers / Q000494:pharmacology*; D024681:Potassium Channels, Calcium-Activated / Q000037:antagonists & inhibitors; D024661:Potassium Channels, Inwardly Rectifying / Q000037:antagonists & inhibitors; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D019789:Tetraethylammonium / Q000494:pharmacology
chemical_list: D017609:Barium Compounds; D002316:Cardiotonic Agents; D002712:Chlorides; D054086:KATP Channels; D026902:Potassium Channel Blockers; D024681:Potassium Channels, Calcium-Activated; D024661:Potassium Channels, Inwardly Rectifying; D013267:Stilbenes; C024986:barium chloride; D019789:Tetraethylammonium; D000077185:Resveratrol; D005905:Glyburide